ClinicalTrials.Veeva

Menu
Research Associates of South Florida | Miami, FL logo

Research Associates of South Florida | Miami, FL

Research site

Site insights

Top conditions

Top treatments

Mirikizumab
Etrasimod
Ozanimod
ABX464
Dupilumab
EDP-305
Risankizumab
AVP-786
Mesalamine
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

15 of 38 total trials

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Active, not recruiting
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Active, not recruiting
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Active, not recruiting
Ulcerative Colitis
Drug: Mirikizumab
Locations recently updated

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess t...

Active, not recruiting
Ulcerative Colitis
Drug: SAR442970
Drug: Placebo

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with modera...

Enrolling
Atopic Dermatitis
Drug: Tilrekimig
Drug: Dupilumab

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Active, not recruiting
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.The objective is to evaluate...

Enrolling
Moderately to Severely Active Crohn Disease
Drug: Obefazimod
Other: Placebo

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis
Combination Product: Survodutide
Combination Product: Placebo matching survodutide

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Combination Product: Placebo
Combination Product: Survodutide

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Enrolling
Bowel; Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

Enrolling
Esophageal Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, s...

Enrolling
Ulcerative Colitis
Crohn's Disease
Drug: ABBV-701
Drug: Risankizumab

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
A
Celgene logo
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo
Exact Sciences Corporation logo
Ferring logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems